Next Article in Journal
Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells
Next Article in Special Issue
ARH1 in Health and Disease
Previous Article in Journal
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
Previous Article in Special Issue
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
Open AccessReview

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

by Ahrum Min 1,2 and Seock-Ah Im 1,2,3,4,*
1
Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea
2
Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea
3
Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea
4
Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(2), 394; https://doi.org/10.3390/cancers12020394
Received: 30 December 2019 / Revised: 1 February 2020 / Accepted: 5 February 2020 / Published: 8 February 2020
(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation). PARP inhibitors, which inhibit PARylation through competitively binding to NAD+ binding site of PARP1 and PARP2, have improved clinical benefits for BRCA mutated tumors, leading to their accelerated clinical application. However, the antitumor activities of PARP inhibitors in clinical development are different, due to PARP trapping activity beyond blocking PARylation reactions. In this review, we comprehensively address the current state of knowledge regarding the mechanisms of action of PARP inhibitors. We will also discuss the different effects of PARP inhibitors in combination with cytotoxic chemotherapeutic agents regarding the mechanism of regulating PARylation. View Full-Text
Keywords: PARP; PARP inhibitors; PARylation; trapping; cancer therapeutic strategy PARP; PARP inhibitors; PARylation; trapping; cancer therapeutic strategy
Show Figures

Figure 1

MDPI and ACS Style

Min, A.; Im, S.-A. PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers 2020, 12, 394.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop